BOTHELL, Wash.--(BUSINESS WIRE)--Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced the issuance of a patent for its second oncology product candidate, TOCOSOL® Camptothecin. The newly issued patent, United States Patent No. 7,223,770 entitled “Tocopherol-Modified Therapeutic Drug Compounds,” is directed to tocopherol-linked prodrugs of camptothecin and camptothecin derivatives.
